Home Uncategorized Bayer initiates phase III study to investigate aflibercept 8 mg in retinal...

Bayer initiates phase III study to investigate aflibercept 8 mg in retinal vein occlusion

57
0

Berlin, May 10, 2023 – Bayer today announced the initiation of the phase III QUASAR study, designed to evaluate the efficacy and safety of aflibercept 8 mg dosed at extended treatment intervals compared to the standard of care, Eylea™ (aflibercept 2 mg) in macular edema secondary to retinal vein occlusion (RVO).The QUASAR clinical trial will measure changes in best corrected visual acuity (BCVA) in patients who receive aflibercept 8 mg with extended treatment intervals after initial monthly doses and those who receive Eylea (aflibercept 2 mg) every 4 weeks…
Read More